Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
KALA BIO ( (KALA) ) has issued an update.
On November 23, 2025, KALA BIO entered into a Securities Purchase Agreement to issue Series AA and Series AAA Convertible Non-Redeemable Preferred Stock, raising up to $6 million. The first closing occurred on November 24, 2025, with $1.8 million raised, and a second closing is expected by March 31, 2026, contingent on stockholder approvals. Additionally, KALA BIO settled a loan with Oxford, reducing outstanding obligations by $7 million through a cash payment and stock issuance. The company also announced leadership changes, including the appointment of David Lazar as CEO, and a voting agreement with Oxford to support board proposals.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
Average Trading Volume: 1,124,071
Technical Sentiment Signal: Sell
Current Market Cap: $5.07M
Learn more about KALA stock on TipRanks’ Stock Analysis page.